Resveratrol and Renal Biomarkers in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

AIM: This study aimed to systematically evaluate the effects of resveratrol (RSV) supplementation on renal injury-related indicators in patients with type 2 diabetes mellitus (T2DM).

DATA SYNTHESIS: This systematic review and meta-analysis included 12 randomized controlled trials (RCTs) with a total of 636 participants with type 2 diabetes. The analysis was conducted exclusively on RCTs to ensure the highest quality of evidence. The pooled results demonstrated no significant changes in blood urea nitrogen (WMD: -0.01; 95% CI: -0.66 to 0.63; P = 0.97) or serum creatinine (SMD: 0.05; 95% CI: -0.13 to 0.23; P = 0.56). Subgroup analyses revealed no significant differences regardless of RSV dose or intervention duration. In contrast, RSV supplementation resulted in a modest reduction in serum uric acid of -0.42 mg/dL (WMD: -0.42; 95% CI: -0.65 to -0.18; P = 0.0005), with low heterogeneity among the included studies (I2 = 0%).

CONCLUSION

This systematic review and meta-analysis provides updated evidence that RSV significantly reduces serum UA levels in patients with T2DM, despite having no significant effects on BUN and SCr. This specific urate-lowering effect suggests a potential role for RSV in managing hyperuricemia, a common comorbidity in T2DM that contributes to renal and cardiovascular risk.

SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420251033457.